Breaking News Instant updates and real-time market news.

CTAS

Cintas

$136.10

-0.77 (-0.56%)

, MU

Micron

$34.18

-0.69 (-1.98%)

17:35
09/26/17
09/26
17:35
09/26/17
17:35

On The Fly: After Hours Movers

UP AFTER EARNINGS: Cintas (CTAS), up 2.9%... Micron (MU), up 2.8%. ALSO HIGHER: Editas Medicine (EDIT), up 3.1% after it received the EMA's orphan medicinal product designation for EDIT-101... Twitter (TWTR), up 1.8% after it said it will start testing longer, 280-character tweets with a small group. DOWN AFTER EARNINGS: Nike (NKE), down 3.2%. ALSO LOWER: Kornit Digital (KRNT), down 12.2% after it cut its third quarter revenue guidance... Westlake Chemical Partners (WLKP), down 8.3% after it filed to sell 4.5M units for limited partners... Intra-Cellular (ITCI), down 7.2% after it filed to sell $150M in common stock... Ascendis Pharma (ASND), down 4.3% after it announced an offering of $125M of ADSs.

CTAS

Cintas

$136.10

-0.77 (-0.56%)

MU

Micron

$34.18

-0.69 (-1.98%)

EDIT

Editas Medicine

$20.30

-0.83 (-3.93%)

TWTR

Twitter

$16.59

-0.39 (-2.30%)

NKE

Nike

$53.70

0.47 (0.88%)

KRNT

Kornit Digital

$17.15

-0.15 (-0.87%)

WLKP

Westlake Chemical Partners

$24.10

0.15 (0.63%)

ITCI

Intra-Cellular

$19.23

-0.57 (-2.88%)

ASND

Ascendis Pharma

$37.10

0.97 (2.68%)

  • 26

    Sep

  • 26

    Sep

  • 26

    Sep

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

CTAS Cintas
$136.10

-0.77 (-0.56%)

06/27/17
06/27/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Impinj (PI) was downgraded to Sector Weight from Overweight by Pacific Crest analyst Brad Erickson based on valuation. 2. Mizuho analyst Haendel St. Juste downgraded Store Capital (STOR) to Neutral from Buy citing fair valuation following recent strength driven by Berkshire Hathaway's (BRK.A) investment. 3. Camtek (CAMT) was downgraded to Hold from Buy by Needham analyst Y. Edwin Mok, as he expects to see some deceleration as the PCB business normalizes and he believes large orders for back-end semi inspections are already reflected in the stock after its recent run-up. 4. Nomura Instinet analyst Dan Dolev downgraded Cintas (CTAS) to Neutral from Buy after lowering his FY18 uniform rental organic growth forecasts to 5% from 7%. 5. Atlantic Equities analyst Barry MacCarthy downgraded Hess Corp. (HES) and Schlumberger (SLB), both to Neutral from Overweight, given his view of the limited prospects for an oil price rebound. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/27/17
NOMU
06/27/17
DOWNGRADE
NOMU
Neutral
Cintas downgraded to Neutral from Buy at Nomura Instinet
Nomura Instinet analyst Dan Dolev downgraded Cintas to Neutral and lowered its price target to $130 from $142. The analyst lowered FY18 uniform rental organic growth forecasts to 5% from 7% saying the G&K integration will slow organic growth near-term and believes shares may take a pause following six years of outperformance.
03/23/17
BARD
03/23/17
NO CHANGE
Target $143
BARD
Outperform
Cintas price target raised to $143 from $135 at Baird
Baird analyst Andrew Wittmann raised his price target on Cintas to $143 from $135 following Q3 results he called excellent. Wittmann reiterated his Outperform rating on Cintas shares, citing the company's great execution and integration of its GK Services acquisition, its improved organic growth, and impressive margins.
06/20/17
BARD
06/20/17
NO CHANGE
Target $143
BARD
Outperform
Cintas Q4 report could come with 'messy' guidance, says Baird
Baird analyst Andrew Wittmann previewed Cintas' Q4 report and said industry trends appear solid, which should ease investor concerns around the G&K Services acquisition integration. Since sales synergies with GK are unlikely in 2018, guidance could be "messy," added Wittman, who maintained his Outperform rating and $143 price target on Cintas shares.
MU Micron
$34.18

-0.69 (-1.98%)

09/21/17
LOOP
09/21/17
NO CHANGE
LOOP
Micron can deliver beat and raise results, says Loop Capital
Loop Capital analyst Betsy Van Hees believes that Micron's Q4 results can beat expectations , driven by tight memory supplies, rising prices and cost reductions. She thinks the company will modestly increase its Q1 guidance, as she thinks that its current guidance is conservative. The analyst raised her price target on the shares to $46 from $40 and keeps a Buy rating on the stock.
09/20/17
DBAB
09/20/17
NO CHANGE
Target $42
DBAB
Buy
Micron price target raised to $42 from $37 at Deutsche Bank
Ahead of next week's results, Deutsche Bank analyst Sidney Ho raised his estimates for Micron to reflect a better than expected pricing environment in the second half of 2017. Investors continue to underestimate the staying power of the current cycle, especially for DRAM, Ho tells investors in a research note. He raised his price target for Micron shares to $42 and keeps a Buy rating on the name.
09/22/17
JPMS
09/22/17
NO CHANGE
Target $40
JPMS
Overweight
Micron's November quarter guidance has upside, says JPMorgan
JPMorgan analyst Harlan Sur sees upside to Micron's November quarter guidance relative to consensus expectations with average selling prices strengthening thus far in September. Further, the analyst believes Micron's demand profile for the remainder of the year continues to strengthen amid "strong" data center spending, Skylake server upgrade cycle, iPhone upgrade cycle, "near-seasonal" PC demand trends and increasing content in automobiles. Ahead of the company's earnings next week, Sur reiterates an Outperform rating on the shares with a $40 price target.
09/21/17
MKMP
09/21/17
NO CHANGE
MKMP
Micron price target raised to $45 from $40 at MKM Partners
MKM Partners analyst Ruben Roy increased his price target on Micron. He says that his checks "indicate expectations for continued positive DRAM trends into Q4 driven by robust server demand and improving mobile demand." He believes that NAND "will likely continue to outperform expectations." Roy keeps a Buy rating on the stock.
EDIT Editas Medicine
$20.30

-0.83 (-3.93%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Editas Medicine initiated with an Overweight at Barclays
Barclays initiated Editas Medicine with an Overweight rating and a $28 price target, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Editas Medicine initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Editas Medicine (EDIT) with a Perform rating saying that while the company currently has the strongest patent position among its CRISPR-based peers, the shares are fairly valued.
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Crispr Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Crispr Therapeutics (CRSP) with a Perform rating saying the company is in a weaker patent position than competitor Editas Medicine (EDIT).
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Intellia Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann stated Intellia Therapeutics (NTLA) with a Perform rating saying the company is currently in a weaker patent position than competitor Editas Medicine (EDIT). The analyst, however, believes Intellia has the strongest partners among the CRISPR-based companies.
TWTR Twitter
$16.59

-0.39 (-2.30%)

08/25/17
JEFF
08/25/17
DOWNGRADE
Target $16
JEFF
Hold
Jefferies cuts Twitter with Google, Facebook and Snap preferred in social video
As previously reported, Jefferies analyst Brent Thill downgraded Twitter (TWTR) to Hold from Buy in a note to investors after the market close yesterday, stating that he prefers Google (GOOGL), Facebook (FB) and Snap (SNAP) as plays on the digital video transition occurring across the social media space. Thill, who thinks Twitter will underperform broader internet and social peers, acknowledged that investors might ask why he is not advising to sell the stock, but he thinks recent management changes could improve the company's declining ARPU in the near-term. Thill lowered his price target on Twitter shares to $16 from $20.
08/30/17
AGIS
08/30/17
NO CHANGE
AGIS
Aegis sees signs of start of advertising recession
After speaking with Bryan Wiener, the Executive Chairman of online and traditional advertising agency 360i, Aegis analyst Victor Anthony said that his commentary, along with earnings results from ad agencies Interpublic Group (IPG) and WPP (WPPGY), leave him of the opinion that an ad recession is underway. Wiener believes Google (GOOG), Facebook (FB) and Amazon (AMZN) will be relatively insulated given they will continue to take share, and Anthony said he would continue to buy Alphabet and Facebook shares. The analyst keeps a Hold rating on Snap (SNAP) and a Sell rating on Twitter (TWTR).
08/31/17
WEDB
08/31/17
INITIATION
Target $12
WEDB
Neutral
Wedbush cites Snap's 'hugely unprofitable' history in Neutral initiation report
Wedbush analyst Michael Pachter initiated Snap (SNAP) last night with a Neutral rating and $12 price target. The shares closed yesterday down 3c to $14.96. Decelerating growth trends, "fierce" competition for user mindshare and advertiser dollars, and a history of being "hugely unprofitable" justify being on the sidelines with respect to the shares, Pachter tells investors in a research note. He notes his $12 price target reflects a slight premium to Twitter's (TWTR) multiple, since Snap "appears to have a longer runway for continued growth," and a discount to Facebook's (FB) multiple, a company with "superior monetization and growth trends."
08/25/17
08/25/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Hold from Buy at Jefferies by analyst Brent Hill, who prefers Google (GOOGL), Facebook (FB) and Snap (SNAP) as plays on the digital video transition occurring across the social media space. Thill, who thinks Twitter will underperform broader internet and social peers, acknowledged that investors might ask why he is not advising to sell the stock, but he thinks recent management changes could improve the company's declining ARPU in the near-term. 2. Ulta Beauty (ULTA) downgraded to Market Perform from Outperform at BMO Capital by analyst Shannon Coyne, who said that there are bright spots ahead for the company, but sees "clouds on the horizon" looking ahead, including a slowing beauty market and department stores that are "upping their collective game." 3. Hormel Foods (HRL) downgraded to Neutral from Outperform at Credit Suisse by analyst Robert Moskow, who said increased volatility in the protein markets has reduced earnings visibility and his confidence in FY2020 margin targets of 15-19%. Moskow sees further risk from the pork industry's 10% expansion in slaughter capacity. 4. TripAdvisor (TRIP) and Shutterstock (SSTK) downgraded to Underperform from Hold at Jefferies. 5. Domino's Pizza (DPZ) downgraded to Hold from Buy at Argus by analyst John Staszak due to concerns about slowing international revenue combined with a potential for a comparable slowdown in domestic sales. The analyst now expects Domino's to post mid-single-digit comp growth following years of double-digit growth and believes margin gains will be limited going forward as the company invests in the business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NKE Nike
$53.70

0.47 (0.88%)

09/19/17
BOFA
09/19/17
NO CHANGE
Target $42
BOFA
Underperform
Nike risk/reward remains unfavorable, says BofA/Merrill
BofA/Merrill analyst Robert Ohmes believes Nike to report Q1 earnings next Tuesday above consensus of 48c given conservative guidance but expects a muted outlook due to weakening data points. Ohmes said retail partner same-store sales have deteriorated from last quarter, SportScan data continues to deteriorate, the promotional environment remains elevated, the company continues to lose share to adidas, the e-commerce channel has become a "dumping ground" for clearance and discounting, and VaporMax sales are not yet meaningful. The analyst maintains his Underperform rating and $42 price target on Nike and said risk/reward remains unfavorable.
09/19/17
09/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Underperform from Market Perform at Wells Fargo with Wells Fargo with analyst Tom Nikic saying with consumers having filled their closets with athletic wear over the past seven years, the category "appears poised to take a breather for now." The analyst cut his price target for the shares to $13 from $17. 2. Kellogg (K) downgraded to Neutral from Overweight at Piper Jaffray with analyst Michael Lavery saying cereal could be at risk from shrinking center store space. 3. Nike (NKE) downgraded to Neutral from Positive at Susquehanna saying that his checks indicate that the North American and European businesses are decelerating as some key categories, especially basketball, have underperformed, resulting in excess inventory that will pressure sales and margins. 4. Synchronoss (SNCR) downgraded to Underperform from Outperform at Raymond James with analyst Tavis McCourt citing the news that Siris Capital is no longer interested in an all-cash transaction for all the outstanding shares of the company and has withdrawn its $18 per share bid from June 22. Further, the analyst believes it increasingly unlikely that the current strategic review will result in an acquisition at a premium and expects share to come under pressure and stay in the range prior to the Siris indication of interest. 5. Sony (SNE) downgraded to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/22/17
PIPR
09/22/17
NO CHANGE
Target $53
PIPR
Neutral
Nike bulls in denial about resurgence of adidas, Piper Jaffray says
Piper Jaffray analyst Erinn Murphy says her intra-quarter reads point to ongoing deceleration in Nike (NKE) momentum, increasing concern around the Jordan brand, which represents 10% of sales, and intensifying promotional pressure on the category domestically. Bulls on Nike are still denying the durability of adidas' (ADDYY) resurgence, Murphy tells investors in a pre-earnings research note. The analyst believes adidas' market share gains have "longer growth sustainability." For Nike's Q1 results on September 26, Murphy sees revenue as inline "at best" and gross margin worse than expected. The analyst, however, sees cost controls driving an earnings beat. Murphy also sees risk to Nike's outlook for Q2. She keeps a Neutral rating on the shares with a $53 price target.
09/26/17
BERN
09/26/17
NO CHANGE
BERN
Survey respondents more likely to buy Nike for fashion/function, says Bernstein
Bernstein analyst Jamie Merriman says he and his firm surveyed 1000 people in the U.S. in July, asking them about 22 athletic apparel and footwear brands. At the athletic apparel and footwear category level, 58% of survey respondents expect to spend about the same amount on the category as they have spent over the last 12 months, while 28% expect to spend more and 14% expect to spend less, he notes. Among those who had shopped the brands in the LTM, the analyst says theintention to purchase more in the NTM was similar across Nike (NKE), adidas (ADDYY) and Under Armour (UAA), while Lululemon (LULU) customers reported the highest intention to purchase more going forward. Additionally, Merriman said respondents were most likely to purchase Nike, relative to other brands, for a combination of fashion and function.
KRNT Kornit Digital
$17.15

-0.15 (-0.87%)

08/18/17
ADAM
08/18/17
NO CHANGE
Target $24
ADAM
Buy
Kornit Digital weakness a buying opportunity, says Canaccord
Canaccord analyst Bobby Burleson noted Kornit Digital shares are down 17% since its Q2 earnings call and he said he sees no news to justify its fall. He continues to expect growth acceleration in 2018 and expects the stock to trade closer to its top line growth allowing for nearly 40% upside from current levels. Burleson reiterated his Buy rating and $24 price target on Kornit Digital shares.
08/18/17
ADAM
08/18/17
NO CHANGE
Target $24
ADAM
Buy
Kornit Digital weakness a buying opportunity, says Canaccord
Canaccord analyst Bobby Burleson noted Kornit Digital shares are down 17% since its Q2 earnings call and he said he sees no news to justify its fall. He continues to expect growth acceleration in 2018 and expects the stock to trade closer to its top line growth allowing for nearly 40% upside from current levels. Burleson reiterated his Buy rating and $24 price target on Kornit Digital shares.
07/11/17
CHLM
07/11/17
INITIATION
Target $26
CHLM
Buy
Kornit Digital initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Greg Palm initiated Kornit Digital with a Buy rating and $26 price target, citing a large untapped market in digital garment printing, the digital printing technology enabling a new retail model, and Amazon (AMZN) as an early adopter with their deal with Kornit Digital.
09/12/17
WBLR
09/12/17
NO CHANGE
WBLR
Outperform
William Blair continues to see 'material upside' in Kornit Digital shares
After assessing the outlook for the company, William Blair analyst Brian Drab says he continues to see "material upside" in Kornit Digital shares over the next 12-18 months. The analyst continues to view Kornit's technology as differentiated within the textile printing industry. He expects the company to sustain double-digit revenue and earnings growth rates and keeps an Outperform rating on the name.
WLKP Westlake Chemical Partners
$24.10

0.15 (0.63%)

01/20/17
TUDR
01/20/17
UPGRADE
TUDR
Buy
Westlake Chemical Partners upgraded to Buy from Hold at Tudor Pickering
ITCI Intra-Cellular
$19.23

-0.57 (-2.88%)

08/30/17
LTCO
08/30/17
UPGRADE
Target $36
LTCO
Buy
Intra-Cellular upgraded to Buy with $36 target at Ladenburg
Ladenburg Thalmann analyst Christopher James upgraded Intra-Cellular Therapies to Buy from Neutral with a $36 price target. The shares in early trading are up 6%, or 99c, to $16.89. Current studies of lumateperone, which has a better side-effect profile than current schizophrenia medications, appear "sufficient for approval," James told investors earlier in a research note. He believes the drug could reach sales over $1B if Intra-Cellular can secure indications for bipolar depression and agitation in patients with dementia.
09/07/17
PIPR
09/07/17
UPGRADE
PIPR
Overweight
Intra-Cellular upgraded to Overweight from Neutral at Piper Jaffray
09/07/17
09/07/17
UPGRADE
Target $33

Overweight
Intra-Cellular upgraded to Overweight after schizophrenia data at Piper Jaffray
As previously reported, Piper Jaffray analyst Charles Duncan upgraded Intra-Cellular to Overweight from Neutral after the company reported data from its "switching" study of lumateperone in schizophrenia outpatients on approved antipsychotics. He said the trial gives "some of the strongest evidence to date" that lumateperone is differentiated on a range of side effects from the current standard of care. Duncan raised his price target on Intra-Cellular to $33 from $14.
09/08/17
COWN
09/08/17
NO CHANGE
Target $27
COWN
Outperform
Intra-Cellular price target raised to $27 from $20 at Cowen
Cowen analyst Ritu Baral raised her price target on Intra-Cellular to $27 from $20 following the release of top-line Phase 3 switch data on the long-term safety of its lead drug lumateperone in schizophrenia. She is cautious on the meaningfulness of superior efficacy signals but sees them as solid evidence of maintenance of clinical control with lumateperone. Baral maintained her Outperform rating on Intra-Cellular shares.
ASND Ascendis Pharma
$37.10

0.97 (2.68%)

09/26/17
BOFA
09/26/17
NO CHANGE
Target $46
BOFA
Ascendis Pharma price target raised to $46 from $36 at BofA/Merrill
09/22/17
FBCO
09/22/17
NO CHANGE
Target $50
FBCO
Outperform
Ascendis Pharma price target raised to $50 from $30 at Credit Suisse
Credit Suisse analyst Alethia Young said she now believes Ascendis Pharma's (ASND) TransCon hGH can have dominant market share if its Phase 3 trial succeeds after Versartis' (VSAR) non-inferiority study testing somavaratan failed. Ascendis now has the potential to be first to market in pediatric with their weekly growth hormone drug and she has raised her peak sale estimate for TransCon hGH to $1.2B from $820M, she tells investors. Young raised her price target on Ascendis shares to $50 from $30 and keeps an Outperform rating on the stock, which is up nearly 40% to $38.68 in pre-market trading.
09/22/17
WEDB
09/22/17
NO CHANGE
Target $65
WEDB
Outperform
Ascendis Pharma price target raised to $65 from $36 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Ascendis Pharma (ASND) shares to $65 after Versartis (VSAR) said the Phase 3 Velocity trial testing somavaratan long-acting growth hormone as a treatment for pediatric growth hormone deficiency failed to meet its endpoint. Competitor somavaratan is no longer a threat to Ascendis, Moussatos tells investors in a research note. Her new price target reflects increased penetration due to reduced competition. Moussatos reiterates an Outperform rating on Ascendis. The stock in premarket trading is up 39%, or $10.71, to $38.45.
09/26/17
BOFA
09/26/17
NO CHANGE
Target $46
BOFA
Buy
BofA/Merrill ups Ascendis target to $46 after talking to physicians
BofA/Merrill analyst Tazeen Ahmad raised his price target on shares of Ascendis Pharma to $46 from $36 after speaking with two "expert" physicians who treat pediatric growth hormone deficiency. Feedback indicates U.S. doctors want to have access to multiple GHD treatment options, Ahmad tells investors in a research note. The analyst raised his peak worldwide penetration of the pediatric GHD market for Ascendis' Trans Con Growth Hormone to 27% from 25%. He believes TCGH is well positioned to be the first approved long-acting therapy for pediatric GHD and that Ascendis' pipeline could be undervalued. The analyst reiterates a Buy rating on the shares.

TODAY'S FREE FLY STORIES

GNRC

Generac

$50.49

-0.4 (-0.79%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Recommendations
Generac analyst commentary  »

Generac estimates raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

ADP

ADP

$113.72

-0.86 (-0.75%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Periodicals
Ackman increases pressure on ADP over tech development, WSJ reports »

Activist investor and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

PRKR

ParkerVision

$1.50

-0.06 (-3.85%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Hot Stocks
ParkerVision enters common stock purchase agreement with Aspire Capital »

ParkerVision announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$9.23

0.15 (1.65%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Technical Analysis
Technical View: GoPro trades higher, analyst action »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NAVI

Navient

$12.20

0.47 (4.01%)

07:17
10/18/17
10/18
07:17
10/18/17
07:17
Hot Stocks
Navient sees adding over $1B of education refinance loans in FY17 »

Including the planned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Conference/Events
Commodity Futures Trading Commission Commissioners to speak at Expo »

Brian Quintenz and Rostin…

FGEN

FibroGen

$55.30

0.8 (1.47%)

, AZN

AstraZeneca

$34.78

0.13 (0.38%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Hot Stocks
FibroGen announces CFDA acceptance of roxadustat NDA »

FibroGen (FGEN) and its…

FGEN

FibroGen

$55.30

0.8 (1.47%)

AZN

AstraZeneca

$34.78

0.13 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 08

    Nov

  • 09

    Nov

CMG

Chipotle

$329.30

8.91 (2.78%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Technical Analysis
Technical View: Chipotle falls, analyst actions »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

UNH

UnitedHealth

$203.89

10.69 (5.53%)

, AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Recommendations
UnitedHealth, Amazon.com analyst commentary  »

UnitedHealth price target…

UNH

UnitedHealth

$203.89

10.69 (5.53%)

AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

  • 18

    Mar

AAN

Aaron's

$41.55

0.01 (0.02%)

07:15
10/18/17
10/18
07:15
10/18/17
07:15
Initiation
Aaron's initiated  »

Aaron's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

BMTC

Bryn Mawr Bank

$44.50

-0.1 (-0.22%)

, FCF

First Commonwealth

$13.94

-0.26 (-1.83%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Conference/Events
FDIC to hold a committee meeting »

The FDIC's Advisory…

BMTC

Bryn Mawr Bank

$44.50

-0.1 (-0.22%)

FCF

First Commonwealth

$13.94

-0.26 (-1.83%)

ONB

Old National Bancorp

$18.40

-0.05 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

HCC

Warrior Met Coal

$24.04

0.51 (2.17%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Downgrade
Warrior Met Coal rating change  »

Warrior Met Coal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$61.54

1.68 (2.81%)

, UNH

UnitedHealth

$203.89

10.69 (5.53%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Periodicals
Health insurers prepare for enrollment drop amid ACA uncertainty, WSJ says »

As enrollment for 2018…

MOH

Molina Healthcare

$61.54

1.68 (2.81%)

UNH

UnitedHealth

$203.89

10.69 (5.53%)

CNC

Centene

$93.80

2.88 (3.17%)

WCG

WellCare

$174.03

6.11 (3.64%)

CI

Cigna

$187.20

2.21 (1.19%)

ANTM

Anthem

$187.26

3.5 (1.90%)

HNT

Health Net

HUM

Humana

$240.43

3.26 (1.37%)

AET

Aetna

$155.90

4.46 (2.95%)

EHTH

eHealth

$23.79

-0.61 (-2.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 31

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 14

    Dec

IBM

IBM

$146.54

-0.29 (-0.20%)

07:12
10/18/17
10/18
07:12
10/18/17
07:12
Recommendations
IBM analyst commentary  »

IBM reported 'best…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 15

    Nov

NVO

Novo Nordisk

$49.31

-0.01 (-0.02%)

07:12
10/18/17
10/18
07:12
10/18/17
07:12
Conference/Events
FDA Endocrinologic & Metabolic Drugs Advisory Committee to hold a meeting »

The Committee discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSLA

Tesla

$355.75

5.15 (1.47%)

07:11
10/18/17
10/18
07:11
10/18/17
07:11
Periodicals
Tesla employees claim dismissals not performance related, CNBC reports »

Tesla is trying to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ATTU

Attunity

$6.90

0.12 (1.77%)

07:11
10/18/17
10/18
07:11
10/18/17
07:11
Hot Stocks
Attunity's Replicate adopted by large health insurance provider »

Attunity announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

MYGN

Myriad Genetics

$35.84

-0.26 (-0.72%)

07:10
10/18/17
10/18
07:10
10/18/17
07:10
Hot Stocks
Myriad Genetics BRACAnalysis CDx sPMA by FDA for review »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

MAIN

Main Street

$40.07

-0.1 (-0.25%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Hot Stocks
Main Street announces semi-annual supplemental cash dividend of 27.5c per share »

Main Street Capital is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

JNJ

Johnson & Johnson

$140.79

4.67 (3.43%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Recommendations
Johnson & Johnson analyst commentary  »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

IONS

Ionis Pharmaceuticals

$63.85

2.7 (4.42%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Hot Stocks
Ionis collaborates with Seventh Sense Biosystems in blood collection device »

Ionis Pharmaceuticals has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 26

    Oct

LRCX

Lam Research

$194.55

2.19 (1.14%)

07:08
10/18/17
10/18
07:08
10/18/17
07:08
Recommendations
Lam Research analyst commentary  »

Lam Research price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMRN

Immuron

$5.03

0.1 (2.03%)

07:06
10/18/17
10/18
07:06
10/18/17
07:06
Initiation
Immuron initiated  »

Immuron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLRX

BioLineRx

$1.09

-0.065 (-5.63%)

, RHHBY

Roche

$31.45

0.27 (0.87%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Hot Stocks
BioLineRx: Genentech initiates Phase 1b/2 trial for BL-8040 »

BioLineRx (BLRX)…

BLRX

BioLineRx

$1.09

-0.065 (-5.63%)

RHHBY

Roche

$31.45

0.27 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

CEVA

CEVA

$45.40

0.1 (0.22%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Hot Stocks
CEVA and Brodmann17 partner for deep learning in edge devices »

CEVA and Broadmann17, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.